&nbsp;

H-YSM_GeneralFAQ.pdf

Jun 2023

Document

H-YSM_GeneralFAQ-FR.pdf

Jun 2023

Regimen

BEVA+PEMB(MNT)

Cancer Type:

Gynecologic,

Cervix

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - Metastatic, Persistent, or Recurrent Carcinoma of the Cervix

New Drug Funding Program

Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix

Drugs Used:

pembrolizumab,

bevacizumab

... Show more tags

Quick Link(s):

Regimen Monograph

Nov 2023

Document

H-YSM_VolunteerTrainingResource_FR.pptx

Jun 2023

Regimen

BEACOPDAC(ESC)

Cancer Type:

Hematologic,

Lymphoma - Hodgkin

Intent: Curative

Funding:

ODB - General Benefit

prednisone

Drugs Used:

Quick Link(s):

Regimen Monograph

Aug 2023

Regimen

BEACOPDAC-14

Cancer Type:

Hematologic,

Lymphoma - Hodgkin

Intent: Curative

Funding:

ODB - General Benefit

prednisone

Drugs Used:

Quick Link(s):

Regimen Monograph

Aug 2023

Regimen

BORTDEXALENA(LD)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - In Combination with Lenalidomide and Dexamethasone for Previously Untreated Multiple Myeloma Pre-SCT

ODB Limited Use

lenalidomide - Induction therapy for transplant eligible, newly diagnosed multiple myeloma, according to clinical criteria

ODB - General Benefit

dexamethasone

Drugs Used:

Quick Link(s):

Regimen Monograph

Dec 2023

Document

HCP-Switching-Reference-Biologics-to-Biosimilar-Biologics.pdf

Jan 2024

Document

HCP-Switching-Reference-Biologics-to-Biosimilar-Biologics-FR.pdf

Jan 2024

Document

basic-template

May 2024

Document